References
- 1. K. M. De Bruijn, L. R. Arends, B. E. Hansen, S. Leeflang, R. Ruiter and C. H. van Eijck, Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer, Br. J. Surg. 100 (2013) 1421-1429; http://doi.org/10.1002/bjs.9229
- 2. WHO, Global Status Report on Noncommunicable Diseases 2010, Description of the Global Burden of NCDs, Their Risk Factors and Determinants, World Health Organization, Geneva, Switzerland, 2011.
- 3. Z. J. Zhang and S. Li, The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis, Diabetes Obes. Metab. 16 (2014) 707-710; http://doi.org/10.1111/dom.12267
- 4. I. Wolf, S. Sadetzki, R. Catane, A. Karasik and B. Kaufman, Diabetes mellitus and breast cancer, Lancet Oncol. 6 (2005) 103-111; http://doi.org/10.1016/S1470-2045(05)01736-5
- 5. K. S. Peairs, B. B. Barone, C. F. Snyder, H. C. Yeh, K. B. Stein, R. L. Derr, F. L. Brancati and A. C. Wolff, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis, J. Clin. Oncol. 29 (2011) 40-46; http://doi.org/10.1200/JCO.2009.27.3011
- 6. D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646-674; http://doi.org/10.1016/j.cell.2011.02.013
- 7. C. Catsburg, M. J. Gunter, C. Chen, M. L. Cote, G. C. Kabat, R. Nassir, L. Tinker, J. Wactawski- Wende, D. L. Page and T. E. Rohan, Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease, Cancer Res. 74 (2014) 3248-3258; http://doi.org/10.1158/0008-5472.CAN-13-3514
- 8. M. Jalving, J. A. Gietema, J. D. Lefrandt, S. de Jong, A. K. Reyners, R. O. Gans and E. G. de Vries, Metformin: taking away the candy for cancer?, Eur. J. Cancer 46 ( 2010) 2 369-2380; h ttp://doi.org/10.1016/j.ejca.2010.06.012
- 9. J. H. Scarpello and H. C. Howlett, Metformin therapy and clinical uses, Diab. Vasc. Dis. Res. 5(2008) 157-167; http://doi.org/10.3132/dvdr.2008.027
- 10. W. C. Knowler, E. Barrett-Connor, S. E. Fowler, R. F. Hamman, J. M. Lachin, E. A. Walker and D. M. Nathan, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med. 346 (2002) 393-403; http://doi.org/10.1056/NEJMoa012512
- 11. Y. Zhuang and W. K. Miskimins, Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J. Mol. Signal.3 (2008) 18; http://doi.org/10.1186/1750-2187-3-18
- 12. M. Alalem, A. Ray and B. K. Ray, Metformin induces degradation of mTOR protein in breast cancer cells, Cancer Med. 5 (2016) 3194-3204; http://doi.org/10.1002/cam4.896
- 13. P. J. Goodwin, V. Stambolic, J. Lemieux, B. E. Chen, W. R. Parulekar, K. A. Gelmon, D. L. Hershman, T. J. Hobday, J. A. Ligibel, I. A. Mayer, K. I. Pritchard, T. J. Whelan, P. Rastogi and L. E. Shepherd, Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents, Breast Cancer Res. Treat. 126 (2011) 215-220; http://doi.org/10.1007/s10549-010-1224-1
- 14. M. A. Khanfar, S. K. Bardaweel, M. R. Akl and K. A. El Sayed, Olive oil-derived oleocanthal as potent inhibitor of mammalian target of rapamycin: Biological evaluation and molecular modeling studies, Phytother. Res. 29 (2015) 1776-1782; http://doi.org/10.1002/ptr.5434
- 15. M. R. Owen, E. Doran and A. P. Halestrap, Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain, Biochem. J. 348 (2000)607-614.